title: Deacetylase inhibitors for the treatment of myelodysplastic syndromes.
abstract: Myelodysplastic syndromes (MDS) are a diverse group of myeloid disorders, with patients being at risk for cytopenias or progression to acute myeloid leukemia. Several classification and prognostic scoring systems have been developed. High-intensity treatments are not appropriate for all patients. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of MDS, although many patients do not derive long-term benefit and eventually progress. Deacetylase inhibitors have emerged as novel treatment candidates based on mechanistic rationale and preliminary data. This article reviews existing data on MDS treatment and discusses the rationale and potential for combination with deacetylase inhibitors.
authors: Leukemia Department, M. D. Anderson Cancer Center , Houston, TX , USA.
authors: Elias
authors: E
authors: Jabbour
authors: Guillermo
authors: G
authors: Garcia-Manero
mesh_terms: D019175:DNA Methylation / Q000187:drug effects; D004359:Drug Therapy, Combination; D044127:Epigenesis, Genetic / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D056572:Histone Deacetylase Inhibitors
keywords: Deacetylase inhibitor; acute myeloid leukemia; myelodysplastic syndromes